Press Release

AB-Therapeutics Hires José Alfón as Director of Development

Alfón, previously at Palau Pharma, will head the Catalan company’s R&D

January 3, 2011

The Catalan biotechnology company AB-Therapeutics, that focuses on drug development, has just hired José Alfón as Director of Development. Alfón previously served as Drug Development Project Leader at Palau Pharma.

In bringing Alfón aboard, AB-Therapeutics has finished putting together a solid team of scientists with broad international experience. His mission will be to direct the company’s recently begun preclinical development program for an anti-cancer drug candidate through the clinical phase.

José Alfón, 43, earned a Bachelor of Pharmacy and an MS in Pharmaceutical Sciences from the Hebrew University of Jerusalem, and a PhD in Pharmaceutical Sciences from the University of Barcelona (UB). He has over ten years experience in identifying drug candidates and in developing drugs from the discovery stage to Phase II clinical trials. In addition to Palau Pharma, where has spent most of his career to date, he has also held various research positions at the Hebrew University of Jerusalem, the Spanish National Research Council (CSIC), and different hospitals in the UK and Israel.

ABOUT AB-THERAPEUTICS

AB-Therapeutics, SL is a drug discovery and development company headquartered in Barcelona, Catalonia, Spain, with planned US facilities in Boston. The company was cofounded in late 2009 by AB Biotics, SA, a company publicly traded at the Spanish alternative stock market (MAB), Carles Domenech (CEO) and Jordi Espadaler (VP Discovery Research).

AB-Therapeutics, SL develops safer human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. It has a molecule ready to start preclinical development in 4Q2010, with Phase I clinical trials (first in man) starting in late 2011 / early 2012. A second drug candidate will start preclinical development in 2Q2011.

Contact:
 
Media relations:
Nuria Peláez
Tel. +34 902 903 844
media.relations@ab-therapeutics.com
 
Investors:
Carles Domènech, PhD
Tel. +34 935 868 977
contact@ab-therapeutics.com

LATEST NEWS

11.03.2024

Press Release

AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023

Press Release

Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022

Press Release

AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022

Press Release

AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022

Press Release

AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
02.11.2022

Press Release

ABTL0812 shows potential against glioblastoma brain tumors + info
07.10.2022

Press Release

AbilityPharma Secures 2,2M € of Non-Dilutive Funding from the Ministry of Science & Innovation of the Government of Spain to Accelerate the Clinical Development and Regulatory Path of ABTL0812 + info
07.09.2022

Press Release

Carles Domènech, Executive Chairman & CEO of AbilityPharma, Will Attend ESMO Congress in Paris for a Meeting with some of the most Relevant Key Opinion Leaders (KOLs) in the Treatment of Pancreatic Cancer + info
29.06.2022

Press Release

AbilityPharma Will Attend ESMO World Congress on Gastrointestinal Cancer 2022 in Barcelona + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG